BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

664 related articles for article (PubMed ID: 28774880)

  • 1. Randomized phase 2 study of low-dose decitabine vs low-dose azacitidine in lower-risk MDS and MDS/MPN.
    Jabbour E; Short NJ; Montalban-Bravo G; Huang X; Bueso-Ramos C; Qiao W; Yang H; Zhao C; Kadia T; Borthakur G; Pemmaraju N; Sasaki K; Estrov Z; Cortes J; Ravandi F; Alvarado Y; Komrokji R; Sekeres MA; Steensma DP; DeZern A; Roboz G; Kantarjian H; Garcia-Manero G
    Blood; 2017 Sep; 130(13):1514-1522. PubMed ID: 28774880
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Update of the decitabine experience in higher risk myelodysplastic syndrome and analysis of prognostic factors associated with outcome.
    Kantarjian HM; O'Brien S; Shan J; Aribi A; Garcia-Manero G; Jabbour E; Ravandi F; Cortes J; Davisson J; Issa JP
    Cancer; 2007 Jan; 109(2):265-73. PubMed ID: 17133405
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia.
    Kantarjian H; Oki Y; Garcia-Manero G; Huang X; O'Brien S; Cortes J; Faderl S; Bueso-Ramos C; Ravandi F; Estrov Z; Ferrajoli A; Wierda W; Shan J; Davis J; Giles F; Saba HI; Issa JP
    Blood; 2007 Jan; 109(1):52-7. PubMed ID: 16882708
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low-Dose Decitabine versus Low-Dose Azacitidine in Lower-Risk MDS.
    Sasaki K; Jabbour E; Montalban-Bravo G; Darbaniyan F; Do KA; Class C; Short NJ; Kanagal-Shamana R; Kadia T; Borthakur G; Pemmaraju N; Cortes J; Ravandi F; Alvarado Y; Chien K; Komrokji R; Sekeres MA; Steensma DP; DeZern A; Roboz G; Soltysiak K; Yang H; Kantarjian HM; Garcia-Manero G
    NEJM Evid; 2022 Oct; 1(10):EVIDoa2200034. PubMed ID: 38319837
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lack of objective response of myelodysplastic syndromes and acute myeloid leukemia to decitabine after failure of azacitidine.
    Duong VH; Bhatnagar B; Zandberg DP; Vannorsdall EJ; Tidwell ML; Chen Q; Baer MR
    Leuk Lymphoma; 2015 Jun; 56(6):1718-22. PubMed ID: 25263320
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison between 5-day decitabine and 7-day azacitidine for lower-risk myelodysplastic syndromes with poor prognostic features: a retrospective multicentre cohort study.
    Lee BH; Kang KW; Jeon MJ; Yu ES; Kim DS; Choi H; Lee SR; Sung HJ; Kim BS; Choi CW; Park Y
    Sci Rep; 2020 Jan; 10(1):39. PubMed ID: 31913293
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized open-label phase II study of decitabine in patients with low- or intermediate-risk myelodysplastic syndromes.
    Garcia-Manero G; Jabbour E; Borthakur G; Faderl S; Estrov Z; Yang H; Maddipoti S; Godley LA; Gabrail N; Berdeja JG; Nadeem A; Kassalow L; Kantarjian H
    J Clin Oncol; 2013 Jul; 31(20):2548-53. PubMed ID: 23733767
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Decitabine for Treatment of Myelodysplastic Syndromes in Chinese Patients: An Open-Label, Phase-3b Study.
    Wu D; Du X; Jin J; Xiao Z; Shen Z; Shao Z; Li X; Huang X; Liu T; Yu L; Li J; Chen B; He G; Cai Z; Liang H; Li J; Ruan C
    Adv Ther; 2015 Nov; 32(11):1140-59. PubMed ID: 26568466
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcome of patients with high risk Myelodysplastic Syndrome (MDS) and advanced Chronic Myelomonocytic Leukemia (CMML) treated with decitabine after azacitidine failure.
    Harel S; Cherait A; Berthon C; Willekens C; Park S; Rigal M; Brechignac S; Thépot S; Quesnel B; Gardin C; Adès L; Fenaux P; Braun T
    Leuk Res; 2015 May; 39(5):501-4. PubMed ID: 25735917
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low-dose decitabine versus best supportive care in elderly patients with intermediate- or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: final results of the randomized phase III study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group.
    Lübbert M; Suciu S; Baila L; Rüter BH; Platzbecker U; Giagounidis A; Selleslag D; Labar B; Germing U; Salih HR; Beeldens F; Muus P; Pflüger KH; Coens C; Hagemeijer A; Eckart Schaefer H; Ganser A; Aul C; de Witte T; Wijermans PW
    J Clin Oncol; 2011 May; 29(15):1987-96. PubMed ID: 21483003
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study.
    Kantarjian H; Issa JP; Rosenfeld CS; Bennett JM; Albitar M; DiPersio J; Klimek V; Slack J; de Castro C; Ravandi F; Helmer R; Shen L; Nimer SD; Leavitt R; Raza A; Saba H
    Cancer; 2006 Apr; 106(8):1794-803. PubMed ID: 16532500
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes.
    Welch JS; Petti AA; Miller CA; Fronick CC; O'Laughlin M; Fulton RS; Wilson RK; Baty JD; Duncavage EJ; Tandon B; Lee YS; Wartman LD; Uy GL; Ghobadi A; Tomasson MH; Pusic I; Romee R; Fehniger TA; Stockerl-Goldstein KE; Vij R; Oh ST; Abboud CN; Cashen AF; Schroeder MA; Jacoby MA; Heath SE; Luber K; Janke MR; Hantel A; Khan N; Sukhanova MJ; Knoebel RW; Stock W; Graubert TA; Walter MJ; Westervelt P; Link DC; DiPersio JF; Ley TJ
    N Engl J Med; 2016 Nov; 375(21):2023-2036. PubMed ID: 27959731
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison between decitabine and azacitidine for the treatment of myelodysplastic syndrome: a meta-analysis with 1,392 participants.
    Xie M; Jiang Q; Xie Y
    Clin Lymphoma Myeloma Leuk; 2015 Jan; 15(1):22-8. PubMed ID: 25042977
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I/II study of decitabine in patients with myelodysplastic syndrome: a multi-center study in Japan.
    Oki Y; Kondo Y; Yamamoto K; Ogura M; Kasai M; Kobayashi Y; Watanabe T; Uike N; Ohyashiki K; Okamoto S; Ohnishi K; Tomita A; Miyazaki Y; Tohyama K; Mukai HY; Hotta T; Tomonaga M
    Cancer Sci; 2012 Oct; 103(10):1839-47. PubMed ID: 22816487
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Results of phase 2 randomized study of low-dose decitabine with or without valproic acid in patients with myelodysplastic syndrome and acute myelogenous leukemia.
    Issa JP; Garcia-Manero G; Huang X; Cortes J; Ravandi F; Jabbour E; Borthakur G; Brandt M; Pierce S; Kantarjian HM
    Cancer; 2015 Feb; 121(4):556-61. PubMed ID: 25336333
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A prospective, multicenter, observational study of long-term decitabine treatment in patients with myelodysplastic syndrome.
    Jeong SH; Kim YJ; Lee JH; Kim YK; Kim SJ; Park SK; Do YR; Kim I; Mun YC; Kim HG; Lee WS; Yi HG; Joo YD; Choi CW; Kim SR; Na SM; Jang JH
    Oncotarget; 2015 Dec; 6(42):44985-94. PubMed ID: 26517692
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Validation of response assessment according to international consortium for MDS/MPN criteria in chronic myelomonocytic leukemia treated with hypomethylating agents.
    Duchmann M; Braun T; Micol JB; Platzbecker U; Park S; Pilorge S; Beyne-Rauzy O; Vey N; Sébert M; Gruson B; Dumas PY; Guieze R; Chretien ML; Laribi K; Chait Y; Legros L; Sahnes L; Hirsch P; Salanoubat C; Solary E; Fenaux P; Itzykson R
    Blood Cancer J; 2017 May; 7(5):e562. PubMed ID: 28498370
    [No Abstract]   [Full Text] [Related]  

  • 18. Multicenter study of decitabine administered daily for 5 days every 4 weeks to adults with myelodysplastic syndromes: the alternative dosing for outpatient treatment (ADOPT) trial.
    Steensma DP; Baer MR; Slack JL; Buckstein R; Godley LA; Garcia-Manero G; Albitar M; Larsen JS; Arora S; Cullen MT; Kantarjian H
    J Clin Oncol; 2009 Aug; 27(23):3842-8. PubMed ID: 19528372
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized Phase II Study of Azacitidine Alone or in Combination With Lenalidomide or With Vorinostat in Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: North American Intergroup Study SWOG S1117.
    Sekeres MA; Othus M; List AF; Odenike O; Stone RM; Gore SD; Litzow MR; Buckstein R; Fang M; Roulston D; Bloomfield CD; Moseley A; Nazha A; Zhang Y; Velasco MR; Gaur R; Atallah E; Attar EC; Cook EK; Cull AH; Rauh MJ; Appelbaum FR; Erba HP
    J Clin Oncol; 2017 Aug; 35(24):2745-2753. PubMed ID: 28486043
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytogenetic response based on revised IPSS cytogenetic risk stratification and minimal residual disease monitoring by FISH in MDS patients treated with low-dose decitabine.
    Li X; Chang C; He Q; Xu F; Zhang Q; Wu L; Su J; Zhang X; Zhou L; Wu D; Song L; Zhang Z
    Leuk Res; 2013 Nov; 37(11):1516-21. PubMed ID: 24084368
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.